Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K W van Besien

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Experimental Hematology|January 1, 1992
Is interleukin 6 the physiological regulator of thrombopoiesis?J E Straneva, K W van Besien, G Derigs, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1997
Invasive Aspergillus sinusitis during bone marrow transplantationC F Verschraegen, K W van Besien, C Dignani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive managementK W van Besien, I F Khouri, S A Giralt, et al.
Bone Marrow Transplantation|January 2, 1997
Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphomaM de Lima, K W van Besien, S A Giralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary resultsI F Khouri, M J Keating, H M Vriesendorp, et al.
Bone Marrow Transplantation|May 1, 1997
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effectK W van Besien, M de Lima, S A Giralt, et al.
The American Journal of Medicine|March 1, 1996
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histologyK W van Besien, R C Mehra, S A Giralt, et al.
Leukemia & Lymphoma|March 8, 2000
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphomaM L Donato, R E Champlin, K W Van Besien, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Experimental Hematology|January 1, 1992
Is interleukin 6 the physiological regulator of thrombopoiesis?J E Straneva, K W van Besien, G Derigs, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1997
Invasive Aspergillus sinusitis during bone marrow transplantationC F Verschraegen, K W van Besien, C Dignani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive managementK W van Besien, I F Khouri, S A Giralt, et al.
Bone Marrow Transplantation|January 2, 1997
Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphomaM de Lima, K W van Besien, S A Giralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary resultsI F Khouri, M J Keating, H M Vriesendorp, et al.
Bone Marrow Transplantation|May 1, 1997
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effectK W van Besien, M de Lima, S A Giralt, et al.
The American Journal of Medicine|March 1, 1996
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histologyK W van Besien, R C Mehra, S A Giralt, et al.
Leukemia & Lymphoma|March 8, 2000
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphomaM L Donato, R E Champlin, K W Van Besien, et al.
Pageof 1